There is tremendous interest in the protein dipeptidyl peptidase 4 (DPP4) as a target in diabetes management and reduction of associated cardiovascular risk. The underlying reasons for this burgeoning interest are manifold. First, DPP4 inhibitor therapy in patients with Type 2 diabetes mellitus (T2DM) resulted in a reduction in proteinuria in the recently concluded "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus - Thrombolysis in Myocardial Infarction 53" (SAVOR-TIMI 53) trial. Second, pharmacological as well as genetic inhibition of DPP4 has proven effective in small animal models of chronic and acute kidney injury. Lastly, the biology of DPP4 in the kidney is beginning to be unraveled with the discovery of non-enzymatic functions for this protein.
- Copyright © 2016, American Journal of Physiology-Renal Physiology